Morepen Laboratories has extended the deadline to hive off its medical devices business to Morepen Medipath Limited until 2027. Valued at ₹197.10 crore, the restructuring aims for operational independence. Additionally, the company declared a final dividend of ₹0.20 per share for FY26 and proposed key leadership elevations for Sanjay Suri and Sushil Suri, subject to shareholder approval at the upcoming AGM on September 26, 2026.
Morepen Laboratories Extends Business Restructuring and Announces Leadership Changes
The medical devices hive-off is now extended to 2027, valued at ₹197.10 crore. A final dividend of ₹0.20 per share has been recommended for FY26.
Reader Takeaway: Hive-off delay adds strategic uncertainty, while high-profile leadership appointments signal intent for structural business evolution.
What just happened
Morepen Laboratories has officially delayed the hive-off of its Medical Devices business to its subsidiary, Morepen Medipath Limited, until 2027. Shareholders are set to vote on this extension during the upcoming 41st Annual General Meeting scheduled for September 26, 2026. The transaction value stands at ₹197.10 crore based on FY26 financials.
Leadership and Management Updates
The company has proposed a significant shift in executive leadership. Sanjay Suri is slated to be elevated from Whole-Time Director to Managing Director effective July 1, 2026, with an annual remuneration package reaching up to ₹14 crore inclusive of incentives. Concurrently, Sushil Suri is proposed for re-appointment as Chairman and Managing Director for a three-year term starting October 2026, with an annual remuneration package cap of ₹16.5 crore.
Dividend and Operational Details
Shareholders on record as of September 19, 2026, are eligible for the recommended final dividend of ₹0.20 per equity share. Additionally, the firm has proposed the ratification of M/s. Vijender Sharma & Co. as cost auditors for the 2026-2027 fiscal year at a fee of ₹2.50 lakh.
Risks to watch
The extension of the medical devices hive-off for a second time may raise investor concerns regarding the speed of execution and potential long-term strategic delays. Furthermore, the substantial remuneration packages proposed for senior leadership will be under investor scrutiny to ensure alignment with future operational performance.
What to track next
Investors should monitor the outcome of the shareholder vote at the AGM and watch for any further updates regarding the operational integration of the medical devices segment into the subsidiary.